Christopher M Clark

Summary

Publications

  1. doi Use of florbetapir-PET for imaging beta-amyloid pathology
    Christopher M Clark
    Avid Radiopharmaceuticals, Philadelphia, Pennsylvania, USA
    JAMA 305:275-83. 2011
  2. pmc Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease
    William T Hu
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, USA
    Neurology 79:897-905. 2012
  3. pmc Cognitive and functional resilience despite molecular evidence of Alzheimer's disease pathology
    Selam Negash
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
    Alzheimers Dement 9:e89-95. 2013
  4. pmc Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104 3339, USA
    Brain 135:170-80. 2012
  5. pmc Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease
    Alice S Chen-Plotkin
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Ann Neurol 69:655-63. 2011
  6. pmc T(1ρ) MRI in Alzheimer's disease: detection of pathological changes in medial temporal lobe
    Mohammad Haris
    CMROI, SBIA, Center for Neurodegenerative Disease Research, Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104 6100, USA
    J Neuroimaging 21:e86-90. 2011
  7. pmc Comparison of xMAP and ELISA assays for detecting cerebrospinal fluid biomarkers of Alzheimer's disease
    Li San Wang
    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
    J Alzheimers Dis 31:439-45. 2012
  8. pmc Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue
    Seok Rye Choi
    Avid Radiopharmaceutical Inc, 3711 Market Street, 7th Floor, Philadelphia, PA 19104, USA
    Alzheimer Dis Assoc Disord 26:8-16. 2012
  9. doi Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography
    David A Wolk
    Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
    J Neurol Neurosurg Psychiatry 83:923-6. 2012
  10. ncbi Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study
    Christopher M Clark
    Avid Radiopharmaceuticals, Philadelphia, PA, USA
    Lancet Neurol 11:669-78. 2012

Collaborators

Detail Information

Publications18

  1. doi Use of florbetapir-PET for imaging beta-amyloid pathology
    Christopher M Clark
    Avid Radiopharmaceuticals, Philadelphia, Pennsylvania, USA
    JAMA 305:275-83. 2011
    ..The ability to identify and quantify brain β-amyloid could increase the accuracy of a clinical diagnosis of Alzheimer disease...
  2. pmc Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease
    William T Hu
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, USA
    Neurology 79:897-905. 2012
    ..Here we aim to determine plasma biomarkers associated with AD in 2 independent cohorts and validate the findings in the multicenter Alzheimer's Disease Neuroimaging Initiative (ADNI)...
  3. pmc Cognitive and functional resilience despite molecular evidence of Alzheimer's disease pathology
    Selam Negash
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
    Alzheimers Dement 9:e89-95. 2013
    ..The aim of the present study was to examine cognitive and cerebral reserve factors associated with resilient functioning in the setting of AD pathology...
  4. pmc Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104 3339, USA
    Brain 135:170-80. 2012
    ..In addition, an Alzheimer's disease pattern of brain atrophy may be a preclinical biomarker of cognitive decline in Parkinson's disease...
  5. pmc Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease
    Alice S Chen-Plotkin
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Ann Neurol 69:655-63. 2011
    ..Most people with Parkinson disease (PD) eventually develop cognitive impairment (CI). However, neither the timing of onset nor the severity of cognitive symptoms can be accurately predicted. We sought plasma-based biomarkers for CI in PD...
  6. pmc T(1ρ) MRI in Alzheimer's disease: detection of pathological changes in medial temporal lobe
    Mohammad Haris
    CMROI, SBIA, Center for Neurodegenerative Disease Research, Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104 6100, USA
    J Neuroimaging 21:e86-90. 2011
    ....
  7. pmc Comparison of xMAP and ELISA assays for detecting cerebrospinal fluid biomarkers of Alzheimer's disease
    Li San Wang
    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
    J Alzheimers Dis 31:439-45. 2012
    ....
  8. pmc Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue
    Seok Rye Choi
    Avid Radiopharmaceutical Inc, 3711 Market Street, 7th Floor, Philadelphia, PA 19104, USA
    Alzheimer Dis Assoc Disord 26:8-16. 2012
    ..This study used human autopsy brain tissue to evaluate the correlation between in vitro florbetapir F 18 binding and Aβ density measured by established neuropathologic methods...
  9. doi Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography
    David A Wolk
    Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
    J Neurol Neurosurg Psychiatry 83:923-6. 2012
    ..Florbetapir-F18 recently demonstrated in vivo correlation with postmortem Aβ histopathology, but has not been directly compared with PiB-C11...
  10. ncbi Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study
    Christopher M Clark
    Avid Radiopharmaceuticals, Philadelphia, PA, USA
    Lancet Neurol 11:669-78. 2012
    ..We therefore prospectively compared the sensitivity and specificity of amyloid PET imaging with neuropathology at autopsy...
  11. pmc Neurodegeneration across stages of cognitive decline in Parkinson disease
    Daniel Weintraub
    Department of Psychiatry, University of Pennsylvania, 3615 Chestnut St, Ste 330, Philadelphia, PA 19104, USA
    Arch Neurol 68:1562-8. 2011
    ..To assess regions and patterns of brain atrophy in patients with Parkinson disease (PD) with normal cognition (PD-NC), mild cognitive impairment (PD-MCI), and dementia-level cognitive deficits (PDD)...
  12. pmc Phosphorylated tau/amyloid beta 1-42 ratio in ventricular cerebrospinal fluid reflects outcome in idiopathic normal pressure hydrocephalus
    Sunil Patel
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Fluids Barriers CNS 9:7. 2012
    ..abstract:..
  13. pmc Ethnoracial differences in the clinical characteristics of Alzheimer's disease at initial presentation at an urban Alzheimer's disease center
    Melissa Gartenberg Livney
    From the Penn Memory Center, University of Pennsylvania, Philadelphia, PA 19104, USA
    Am J Geriatr Psychiatry 19:430-9. 2011
    ....
  14. pmc Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology
    Roy Hamilton
    Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
    Ann Neurol 68:535-40. 2010
    ....
  15. pmc Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease
    William T Hu
    Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
    Acta Neuropathol 120:385-99. 2010
    ....
  16. doi T1rho (T1ρ) MR imaging in Alzheimer's disease and Parkinson's disease with and without dementia
    Mohammad Haris
    Department of Radiology, Center for Magnetic Resonance and Optical Imaging, University of Pennsylvania, B1 Stellar Chance Laboratories, 422 Curie Boulevard, Philadelphia, PA 19104 6100, USA
    J Neurol 258:380-5. 2011
    ..The serial measurement of T(1ρ) in both AD and PD may provide the nature of disease progression and may contribute to their early diagnosis...
  17. pmc Simultaneous HPLC-MS-MS quantification of 8-iso-PGF(2alpha) and 8,12-iso-iPF(2alpha) in CSF and brain tissue samples with on-line cleanup
    Magdalena Korecka
    Department Pathology and Laboratory Medicine, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 878:2209-16. 2010
    ..1g of tissue for 8-iso-PGF(2alpha) and 8,12-iso-iPF(2alpha)-VI, respectively, for the brain tissue method. No ion suppression or enhancement of the detection of 8-isoPGF(2alpha), 8,12-isoPF(2alpha)-VI or both internal standards was found...
  18. pmc Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects
    John Q Trojanowski
    Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Alzheimers Dement 6:230-8. 2010
    ..Further studies in ADNI will refine this model and render the biomarkers studied in ADNI more applicable to routine diagnosis and to clinical trials of disease modifying therapies...